Journal
ACS INFECTIOUS DISEASES
Volume 4, Issue 2, Pages 135-145Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.7b00106
Keywords
aspergillomarasmine A; metallo-beta-lactamase; NDM-1; VIM-2; IMP-7; antibiotic resistance
Categories
Funding
- National Institute of Health (NIH) [GM111926, R01GM121714]
- Miami University
- National Science Foundation [CHM1509285]
- Robert A. Welch Foundation [F-1572, F-1155]
- National Institutes of Health (NIH), through National Institute of Allergy and Infectious Diseases [R01AI100560, R01AI063517, R01AI072219]
- Cleveland Department of Veterans Affairs
- Veterans Affairs Merit Review Program [1I01BX001974]
- Geriatric Research Education and Clinical Center VISN 10
- Utrecht University
- Netherlands Organization for Scientific Research
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072219, R01AI100560, R01AI063517] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM111926, R01GM121714] Funding Source: NIH RePORTER
- Veterans Affairs [I01BX001974] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Metallo-beta-lactamases (MBLs) are a growing threat to the continued efficacy of beta-lactam antibiotics. Recently, aspergillomarasmine A (AMA) was identified as an MBL inhibitor, but the mode of inhibition was not fully characterized. Equilibrium dialysis and metal analysis studies revealed that 2 equiv of AMA effectively removes 1 equiv of Zn(II) from MBLs NDM-1, VIM-2, and IMP-7 when the MBL is at micromolar concentrations. Conversely, H-1 NMR studies revealed that 2 equiv of AMA remove 2 equiv of Co(II) from Co(II)-substituted NDM-1, VIM-2, and IMP-7 when the MBL/AMA are at millimolar concentrations. Our findings reveal that AMA inhibits the MBLs by removal of the active site metal ions required for beta-lactam hydrolysis among the most clinically significant MBLs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available